Spyre CEO sells 15,000 shares under trading plan

Spyre Therapeutics, Inc. Chief Executive Officer Turtle Cameron reported open-market sales of company stock.

(Very High)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. Chief Executive Officer Turtle Cameron reported open-market sales of company stock. On April 1, 2026, he sold a total of 15,000 shares of common stock in two transactions, at weighted average prices of $49.20 and $49.92 per share.

The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. After these transactions, Cameron directly holds 627,540 shares of Spyre Therapeutics common stock, including 116,168 shares that vest in monthly installments through November 2026, contingent on his continued service.

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 2 txns

Insider Turtle Cameron

Role Chief Executive Officer

Sold 15,000 shs ($740K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,344	$49.20	$607K
Sale	Common Stock	2,656	$49.92	$133K

Holdings After Transaction: Common Stock — 627,540 shares (Direct)

Footnotes (4)

F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.
F2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.64 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F3. Includes 116,168 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.
F4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.64 to $50.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 15,000 shares Sale price block 1: $49.20 per share Sale price block 2: $49.92 per share +2 more

5 metrics

Shares sold 15,000 shares Total common shares sold on April 1, 2026

Sale price block 1 $49.20 per share Weighted average price for 12,344 shares sold

Sale price block 2 $49.92 per share Weighted average price for 2,656 shares sold

Shares held after sale 627,540 shares Direct common stock ownership after April 1, 2026 trades

Unvested time-based shares 116,168 shares Included in holdings; vest monthly through November 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, vest in monthly installments, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan financial

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported above is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vest in monthly installments financial

"Includes 116,168 shares of common stock that vest in monthly installments through November 2026"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

common stock financial

"Includes 116,168 shares of common stock that vest in monthly installments"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Spyre Therapeutics (SYRE) report for its CEO?

Spyre Therapeutics CEO Turtle Cameron reported open-market sales of company common stock. On April 1, 2026, he sold 15,000 shares in two transactions as disclosed in a Form 4 insider filing with the Securities and Exchange Commission.

How many Spyre Therapeutics (SYRE) shares did the CEO sell and at what prices?

The CEO sold 15,000 Spyre Therapeutics common shares. One block of 12,344 shares was sold at a weighted average price of $49.20 per share, and another block of 2,656 shares was sold at a weighted average price of $49.92 per share.

How many Spyre Therapeutics (SYRE) shares does the CEO hold after the reported sale?

Following the April 1, 2026 transactions, CEO Turtle Cameron directly holds 627,540 shares of Spyre Therapeutics common stock. This figure includes both fully vested shares and shares that are scheduled to vest over time, subject to continued service conditions.

Was the Spyre Therapeutics (SYRE) CEO stock sale part of a Rule 10b5-1 plan?

Yes. The filing states the transaction was executed under a Rule 10b5-1 trading plan adopted on June 20, 2025. Such plans allow executives to pre-schedule trades, helping separate routine portfolio management from discretionary market-timed decisions.

What portion of the Spyre Therapeutics (SYRE) CEO’s holdings are unvested shares?

The CEO’s reported holdings include 116,168 shares of common stock that vest in monthly installments through November 2026. These shares are subject to his continued service with the company on each vesting date as a condition for delivery.

What does weighted average price mean in the Spyre Therapeutics (SYRE) Form 4?

Weighted average price means the reported sale price reflects multiple trades executed within a price range. The CEO’s shares were sold in separate transactions between specified price bounds, and the company notes detailed price and volume information is available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/03/2026 - 09:30 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turtle Cameron

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		S⁽¹⁾		12,344	D	$49.2⁽²⁾	630,196⁽³⁾	D
Common Stock	04/01/2026		S⁽¹⁾		2,656	D	$49.92⁽⁴⁾	627,540⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.64 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. Includes 116,168 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.64 to $50.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR